Showing results (211-220 of 282) with videos related to
Sort By:
Pageof 29
Gynecologic Oncology|February 1, 1993
Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal deliveryM Markman, D Alberts, S Rubin, et al.Gynecologic Oncology|May 1, 1993
Impact of age on survival of patients with ovarian cancerM Markman, J L Lewis, P Saigo, et al.Journal of Cancer Research and Clinical Oncology|January 11, 1992
Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapyM Markman, W Jones, J L Lewis, et al.Archives of Disease in Childhood. Fetal and Neonatal Edition|April 9, 1999
Immunogenicity of hepatitis B vaccine in preterm infantsO Blondheim, D Bader, M Abend, et al.Journal of Medical Virology|August 1, 1991
Prevalence of HBsAg carriers in native and immigrant pregnant female populations in Israel and passive/active vaccination against HBV of newborns at riskV Bogomolski-Yahalom, E Granot, N Linder, et al.Gastroenterology|May 30, 1998
Circulating xanthine oxidase and neutrophil activation during human liver transplantationE J Pesonen, N Linder, K O Raivio, et al.Gynecologic Oncology|May 1, 1993
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatmentM Markman, T Hakes, B Reichman, et al.Cancer|February 15, 1993
Intraperitoneal chemotherapy in the management of ovarian cancerM Markman, B Reichman, T Hakes, et al.Journal of Cancer Research and Clinical Oncology|January 1, 1993
Diethyldithiocarbamate chemoprotection of carboplatin--induced hematological toxicityP Francis, M Markman, T Hakes, et al.Gynecologic Oncology|December 11, 1992
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancerM Markman, B Reichman, T Hakes, et al.Pageof 29